<DOC>
	<DOCNO>NCT02048163</DOCNO>
	<brief_summary>The purpose study compare incidence nausea vomit follow short intermittent versus prolong intermittent infusion meropenem .</brief_summary>
	<brief_title>Intermittent Versus Continuous Infusion Meropenem Cystic Fibrosis</brief_title>
	<detailed_description>1 . To assess number episode emesis follow short prolonged intermittent infusion meropenem . 2 . To assess number episode emesis correspond peak serum concentration meropenem . 3 . To assess number episode emesis correspond area meropenem serum concentration time curve . 4 . To assess report nausea , measure administered dosage anti-nausea medication , follow short prolonged intermittent infusion meropenem . 5 . To assess report nausea , measure administered dos anti-nausea medication , correspond peak concentration meropenem . 6 . To assess report nausea , measure administered dosage anti-nausea medication , correspond area serum concentration time curve 7 . To assess report nausea , measure patient-reported nausea measure use pictorial scale severity nausea pediatric patient , follow short prolonged intermittent infusion meropenem . 8 . To assess report nausea , measure patient-reported nausea measure use pictorial scale severity correspond peak serum concentration meropenem . 9 . To assess report nausea , measure patient-reported nausea measure use pictorial scale severity correspond area meropenem serum concentration time curve .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>1 . Be admit patient Dayton Children 's Hospital . 2 . Between 7 21 year age . 3 . Have document CF diagnosis one follow clinical feature : 1 . Sweat chloride &gt; 60 mEq/liter determine quantitative pilocarpine iontophoresis test ( QPIT ) . 2 . Two mutation ( well characterize ) cystic fibrosis transmembrane conductive regulator ( CTFR ) gene . 3 . Abnormal nasal potential difference . 4 . Based Hankinson/NHanes III criterion , able elicit FEV1 &gt; 25 % &lt; 95 % predict value admit . 5 . Sputum throat swab specimen positive P. aeruginosa history least one additional sputum culture positive P. aeruginosa within last 12 month . 6 . Are able perform acceptable spirometry session ( define 3 acceptable usable effort per ATS/ERS criterion upon admission ) . 7 . Have smoke tobacco within 28 day prior Visit 1 agree smoke duration study . 8 . Are able give write informed consent ( adult ) assent combination consent legal representative ( ) ( minor ) manner approve Institutional Review Board . 9 . Patient experience symptom CF exacerbation CF : 4 follow 12 sign symptom : Change sputum ; New increase hemoptysis ; Increased cough ; Increased dyspnea ; Malaise , fatigue lethargy ; Temperature 38Â°C ; Anorexia weight loss ; Sinus pain tenderness ; Change sinus discharge ; Change physical examination chest ; Decrease pulmonary function 10 percent previously record value ; Radiographic change indicative pulmonary infection . 1 . History hypersensitivity intolerance meropenem . 2 . History hypersensitivity intolerance granisetron . 3 . Are pregnant , breastfeeding , unwilling practice highly effective method birth control abstinence participation study .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Meropenem</keyword>
	<keyword>Nausea</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>